サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1091243

世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬市場：考察と予測 (2028年まで)

Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Insights, Forecast to 2028
出版日: | 発行: QYResearch | ページ情報: 英文 95 Pages | 納期: 2～3営業日
AI翻訳ツール 提供対象
ご購入後の翻訳ツール提供について

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬市場：考察と予測 (2028年まで)
出版日: 2022年06月20日
発行: QYResearch
ページ情報: 英文 95 Pages
納期: 2～3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、グルカゴン様ペプチド1（GLP-1）ベースの治療薬 (Glucagon-like peptide 1 (GLP-1)-based Therapies) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬の製品概要
  • 市場：タイプ別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の市場規模成長率：タイプ別, 2017 VS 2021 VS 2028
    • Exenatied
    • Liraglutide
    • Lixisenatide
    • Albiglutide
    • Dulaglutide
  • 市場：アプリケーション別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の市場規模成長率：アプリケーション別, 2017 VS 2021 VS 2028
    • Hospital
    • Pharmacy
  • 調査目的
  • 対象期間

第2章 レポート概要

  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売 推定および予測 2017-2028
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益 推定および予測 2017-2028
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：地域別: 2017 VS 2021 VS 2028
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：地域別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：地域別 (2017-2022)
    • 世界の販売 グルカゴン様ペプチド1（GLP-1）ベースの治療薬 ：地域別 (2023-2028)
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：地域別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：地域別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：地域別 (2023-2028)
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第3章 競合：メーカー別

  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：メーカー別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の上位メーカー：販売別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5メーカー： グルカゴン様ペプチド1（GLP-1）ベースの治療薬2021
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：メーカー別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：メーカー別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益市場シェア：メーカー別 (2017-2022)
    • 世界の上位10・上位5企業： グルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益 2021
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売価格：メーカー別 (2017-2022)
  • 競合情勢の分析
    • メーカーの市場集中度 (CR5 and HHI)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の市場シェア：企業タイプ別 (Tier 1, Tier 2, and Tier 3)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬のメーカーの地理的分布
  • M&A, 拡張計画

第4章 市場規模：タイプ別

  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：タイプ別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売実績：タイプ別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売予測：タイプ別 (2023-2028)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売市場シェア：タイプ別 (2017-2028)
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：タイプ別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益実績：タイプ別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益予測：タイプ別 (2023-2028)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益市場シェア：タイプ別 (2017-2028)
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の価格：タイプ別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の価格：タイプ別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の価格予測：タイプ別 (2023-2028)

第5章 市場規模：アプリケーション別

  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：アプリケーション別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売実績：アプリケーション別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売予測：アプリケーション別 (2023-2028)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売市場シェア：アプリケーション別 (2017-2028)
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：アプリケーション別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益実績：アプリケーション別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益予測：アプリケーション別 (2023-2028)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益市場シェア：アプリケーション別 (2017-2028)
  • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の価格：アプリケーション別
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の価格：アプリケーション別 (2017-2022)
    • 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の価格予測：アプリケーション別 (2023-2028)

第6章 北米

  • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：タイプ別
    • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：タイプ別 (2017-2028)
    • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：タイプ別 (2017-2028)
  • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：アプリケーション別
    • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：アプリケーション別 (2017-2028)
    • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：アプリケーション別 (2017-2028)
  • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：国別
    • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：国別 (2017-2028)
    • 北米のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：国別 (2017-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：タイプ別
    • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：タイプ別 (2017-2028)
    • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：タイプ別 (2017-2028)
  • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：アプリケーション別
    • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：アプリケーション別 (2017-2028)
    • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：アプリケーション別 (2017-2028)
  • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：国別
    • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：国別 (2017-2028)
    • 欧州のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：国別 (2017-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア

第8章 アジア太平洋

  • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：タイプ別
    • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：タイプ別 (2017-2028)
    • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：タイプ別 (2017-2028)
  • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：アプリケーション別
    • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：アプリケーション別 (2017-2028)
    • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：アプリケーション別 (2017-2028)
  • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：地域別
    • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：地域別 (2017-2028)
    • アジア太平洋のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：地域別 (2017-2028)
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • 中国の台湾
    • インドネシア
    • タイ
    • マレーシア

第9章 ラテンアメリカ

  • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：タイプ別
    • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：タイプ別 (2017-2028)
    • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：タイプ別 (2017-2028)
  • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：アプリケーション別
    • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：アプリケーション別 (2017-2028)
    • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：アプリケーション別 (2017-2028)
  • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：国別
    • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：国別 (2017-2028)
    • ラテンアメリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：国別 (2017-2028)
    • メキシコ
    • ブラジル
    • アルゼンチン

第10章 中東・アフリカ

  • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：タイプ別
    • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：タイプ別 (2017-2028)
    • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：タイプ別 (2017-2028)
  • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：アプリケーション別
    • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：アプリケーション別 (2017-2028)
    • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：アプリケーション別 (2017-2028)
  • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場規模：国別
    • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の販売：国別 (2017-2028)
    • 中東・アフリカのグルカゴン様ペプチド1（GLP-1）ベースの治療薬の収益：国別 (2017-2028)
    • トルコ
    • サウジアラビア

第11章 企業プロファイル

  • Novo Nordisk
  • AstraZeneca
  • Eli Lily
  • GSK
  • Sanofi
  • Bristol-Myers Squibb

第12章 業界チェーンと販売チャネルの分析

  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 業界チェーン分析
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 主要原材料分析
    • 主要原材料分析
    • 原材料の主要サプライヤー
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 生産形態とプロセス
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 販売およびマーケティング
    • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 販売チャネル
    • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 卸業者
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 顧客

第13章 市場の促進要因, 機会, 課題とリスク要因の分析

  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 業界動向
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場の促進要因
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場の課題
  • グルカゴン様ペプチド1（GLP-1）ベースの治療薬 市場の抑制要因

第14章 世界のグルカゴン様ペプチド1（GLP-1）ベースの治療薬の主な市場調査結果

第15章 付録

図表

List of Tables

  • Table 1. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 2. Major Manufacturers of Exenatied
  • Table 3. Major Manufacturers of Liraglutide
  • Table 4. Major Manufacturers of Lixisenatide
  • Table 5. Major Manufacturers of Albiglutide
  • Table 6. Major Manufacturers of Dulaglutide
  • Table 7. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
  • Table 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
  • Table 9. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022) & (Units)
  • Table 10. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022)
  • Table 11. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2023-2028) & (Units)
  • Table 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2023-2028)
  • Table 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022) & (US$ Million)
  • Table 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2017-2022)
  • Table 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2023-2028) & (US$ Million)
  • Table 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region (2023-2028)
  • Table 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers (2017-2022) & (Units)
  • Table 18. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Manufacturers (2017-2022)
  • Table 19. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Manufacturers (2017-2022) & (US$ Million)
  • Table 20. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Manufacturers (2017-2022)
  • Table 21. Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Manufacturers (2017-2022) &(US$/Unit)
  • Table 22. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 23. Global Glucagon-like peptide 1 (GLP-1)-based Therapies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon-like peptide 1 (GLP-1)-based Therapies as of 2021)
  • Table 24. Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturing Base Distribution and Headquarters
  • Table 25. Manufacturers Glucagon-like peptide 1 (GLP-1)-based Therapies Product Offered
  • Table 26. Date of Manufacturers Enter into Glucagon-like peptide 1 (GLP-1)-based Therapies Market
  • Table 27. Mergers & Acquisitions, Expansion Plans
  • Table 28. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
  • Table 29. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2023-2028) & (Units)
  • Table 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Type (2017-2022)
  • Table 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Type (2023-2028)
  • Table 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
  • Table 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2023-2028) & (US$ Million)
  • Table 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Type (2017-2022)
  • Table 35. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Type (2023-2028)
  • Table 36. Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2017-2022) & (US$/Unit)
  • Table 37. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2023-2028) & (US$/Unit)
  • Table 38. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units)
  • Table 39. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2023-2028) & (Units)
  • Table 40. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Application (2017-2022)
  • Table 41. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Application (2023-2028)
  • Table 42. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
  • Table 43. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2023-2028) & (US$ Million)
  • Table 44. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Application (2017-2022)
  • Table 45. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Application (2023-2028)
  • Table 46. Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application (2017-2022) & (US$/Unit)
  • Table 47. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Application (2023-2028) & (US$/Unit)
  • Table 48. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
  • Table 49. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2023-2028) & (Units)
  • Table 50. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
  • Table 51. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2023-2028) & (US$ Million)
  • Table 52. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units)
  • Table 53. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2023-2028) & (Units)
  • Table 54. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
  • Table 55. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2023-2028) & (US$ Million)
  • Table 56. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
  • Table 57. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2023-2028) & (Units)
  • Table 58. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
  • Table 59. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2023-2028) & (US$ Million)
  • Table 60. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
  • Table 61. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2023-2028) & (Units)
  • Table 62. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
  • Table 63. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2023-2028) & (US$ Million)
  • Table 64. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units)
  • Table 65. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2023-2028) & (Units)
  • Table 66. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
  • Table 67. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2023-2028) & (US$ Million)
  • Table 68. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
  • Table 69. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2023-2028) & (Units)
  • Table 70. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
  • Table 71. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2023-2028) & (US$ Million)
  • Table 72. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
  • Table 73. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2023-2028) & (Units)
  • Table 74. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
  • Table 75. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2023-2028) & (US$ Million)
  • Table 76. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units)
  • Table 77. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2023-2028) & (Units)
  • Table 78. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
  • Table 79. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2023-2028) & (US$ Million)
  • Table 80. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022) & (Units)
  • Table 81. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2023-2028) & (Units)
  • Table 82. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022) & (US$ Million)
  • Table 83. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2023-2028) & (US$ Million)
  • Table 84. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
  • Table 85. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2023-2028) & (Units)
  • Table 86. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
  • Table 87. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2023-2028) & (US$ Million)
  • Table 88. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units)
  • Table 89. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2023-2028) & (Units)
  • Table 90. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
  • Table 91. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2023-2028) & (US$ Million)
  • Table 92. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
  • Table 93. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2023-2028) & (Units)
  • Table 94. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
  • Table 95. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2023-2028) & (US$ Million)
  • Table 96. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2022) & (Units)
  • Table 97. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2023-2028) & (Units)
  • Table 98. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2022) & (US$ Million)
  • Table 99. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2023-2028) & (US$ Million)
  • Table 100. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2022) & (Units)
  • Table 101. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2023-2028) & (Units)
  • Table 102. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2022) & (US$ Million)
  • Table 103. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2023-2028) & (US$ Million)
  • Table 104. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2022) & (Units)
  • Table 105. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2023-2028) & (Units)
  • Table 106. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2022) & (US$ Million)
  • Table 107. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2023-2028) & (US$ Million)
  • Table 108. Novo Nordisk Corporation Information
  • Table 109. Novo Nordisk Description and Major Businesses
  • Table 110. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 111. Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 112. Novo Nordisk Recent Developments
  • Table 113. AstraZeneca Corporation Information
  • Table 114. AstraZeneca Description and Major Businesses
  • Table 115. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 116. AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 117. AstraZeneca Recent Developments
  • Table 118. Eli Lily Corporation Information
  • Table 119. Eli Lily Description and Major Businesses
  • Table 120. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 121. Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 122. Eli Lily Recent Developments
  • Table 123. GSK Corporation Information
  • Table 124. GSK Description and Major Businesses
  • Table 125. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 126. GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 127. GSK Recent Developments
  • Table 128. Sanofi Corporation Information
  • Table 129. Sanofi Description and Major Businesses
  • Table 130. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 131. Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 132. Sanofi Recent Developments
  • Table 133. Bristol-Myers Squibb Corporation Information
  • Table 134. Bristol-Myers Squibb Description and Major Businesses
  • Table 135. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
  • Table 136. Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
  • Table 137. Bristol-Myers Squibb Recent Developments
  • Table 138. Key Raw Materials Lists
  • Table 139. Raw Materials Key Suppliers Lists
  • Table 140. Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors List
  • Table 141. Glucagon-like peptide 1 (GLP-1)-based Therapies Customers List
  • Table 142. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Trends
  • Table 143. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
  • Table 144. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
  • Table 145. Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints
  • Table 146. Research Programs/Design for This Report
  • Table 147. Key Data Information from Secondary Sources
  • Table 148. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Glucagon-like peptide 1 (GLP-1)-based Therapies Product Picture
  • Figure 3. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Type in 2021 & 2028
  • Figure 3. Exenatied Product Picture
  • Figure 4. Liraglutide Product Picture
  • Figure 5. Lixisenatide Product Picture
  • Figure 6. Albiglutide Product Picture
  • Figure 7. Dulaglutide Product Picture
  • Figure 8. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Application in 2021 & 2028
  • Figure 9. Hospital
  • Figure 10. Pharmacy
  • Figure 11. Glucagon-like peptide 1 (GLP-1)-based Therapies Report Years Considered
  • Figure 12. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales 2017-2028 (Units)
  • Figure 13. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 14. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue 2017-2028 (US$ Million)
  • Figure 15. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Region in Percentage: 2021 Versus 2028
  • Figure 16. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2017-2022)
  • Figure 17. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Region (2023-2028)
  • Figure 18. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales YoY (2017-2028) & (Units)
  • Figure 19. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue YoY (2017-2028) & (US$ Million)
  • Figure 20. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales YoY (2017-2028) & (Units)
  • Figure 21. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue YoY (2017-2028) & (US$ Million)
  • Figure 22. Asia-Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales YoY (2017-2028) & (Units)
  • Figure 23. Asia-Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue YoY (2017-2028) & (US$ Million)
  • Figure 24. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales YoY (2017-2028) & (Units)
  • Figure 25. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue YoY (2017-2028) & (US$ Million)
  • Figure 26. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales YoY (2017-2028) & (Units)
  • Figure 27. Middle East & Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue YoY (2017-2028) & (US$ Million)
  • Figure 28. The Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
  • Figure 29. The Top 5 and 10 Largest Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies in the World: Market Share by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2021
  • Figure 30. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
  • Figure 31. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • Figure 32. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • Figure 33. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • Figure 34. Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • Figure 35. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • Figure 36. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • Figure 37. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • Figure 38. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • Figure 39. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Country (2017-2028)
  • Figure 40. North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Country (2017-2028)
  • Figure 41. United States Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 42. Canada Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 43. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • Figure 44. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • Figure 45. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • Figure 46. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • Figure 47. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Country (2017-2028)
  • Figure 48. Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Country (2017-2028)
  • Figure 49. Germany Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 50. France Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 51. U.K. Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 52. Italy Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 53. Russia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 54. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • Figure 55. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • Figure 56. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • Figure 57. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • Figure 58. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Region (2017-2028)
  • Figure 59. Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Region (2017-2028)
  • Figure 60. China Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 61. Japan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 62. South Korea Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 63. India Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 64. Australia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 65. China Taiwan Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 66. Indonesia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 67. Thailand Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 68. Malaysia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 69. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • Figure 70. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • Figure 71. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • Figure 72. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • Figure 73. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Country (2017-2028)
  • Figure 74. Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Country (2017-2028)
  • Figure 75. Mexico Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 76. Brazil Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 77. Argentina Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 78. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • Figure 79. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • Figure 80. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • Figure 81. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • Figure 82. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Share by Country (2017-2028)
  • Figure 83. Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Share by Country (2017-2028)
  • Figure 84. Turkey Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 85. Saudi Arabia Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 86. UAE Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue (2017-2028) & (US$ Million)
  • Figure 87. Glucagon-like peptide 1 (GLP-1)-based Therapies Value Chain
  • Figure 88. Glucagon-like peptide 1 (GLP-1)-based Therapies Production Process
  • Figure 89. Channels of Distribution
  • Figure 90. Distributors Profiles
  • Figure 91. Bottom-up and Top-down Approaches for This Report
  • Figure 92. Data Triangulation
  • Figure 93. Key Executives Interviewed
目次

This research report focuses on the Glucagon-like peptide 1 (GLP-1)-based Therapies Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

  • 1.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Product Introduction
  • 1.2 Market by Type
    • 1.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Exenatied
    • 1.2.3 Liraglutide
    • 1.2.4 Lixisenatide
    • 1.2.5 Albiglutide
    • 1.2.6 Dulaglutide
  • 1.3 Market by Application
    • 1.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Hospital
    • 1.3.3 Pharmacy
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Executive Summary

  • 2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Estimates and Forecasts 2017-2028
  • 2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Estimates and Forecasts 2017-2028
  • 2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region: 2017 VS 2021 VS 2028
  • 2.4 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region
    • 2.4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2022)
    • 2.4.2 Global Sales Glucagon-like peptide 1 (GLP-1)-based Therapies by Region (2023-2028)
  • 2.5 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region
    • 2.5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2022)
    • 2.5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2023-2028)
  • 2.6 North America
  • 2.7 Europe
  • 2.8 Asia-Pacific
  • 2.9 Latin America
  • 2.10 Middle East & Africa

3 Competition by Manufacturers

  • 3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Manufacturers
    • 3.1.1 Global Top Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers by Sales (2017-2022)
    • 3.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Manufacturers (2017-2022)
    • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Glucagon-like peptide 1 (GLP-1)-based Therapies in 2021
  • 3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Manufacturers
    • 3.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Manufacturers (2017-2022)
    • 3.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Manufacturers (2017-2022)
    • 3.2.3 Global Top 10 and Top 5 Companies by Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue in 2021
  • 3.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Price by Manufacturers (2017-2022)
  • 3.4 Analysis of Competitive Landscape
    • 3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 3.4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Manufacturers Geographical Distribution
  • 3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

  • 4.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type
    • 4.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Historical Sales by Type (2017-2022)
    • 4.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecasted Sales by Type (2023-2028)
    • 4.1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Type (2017-2028)
  • 4.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type
    • 4.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Historical Revenue by Type (2017-2022)
    • 4.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecasted Revenue by Type (2023-2028)
    • 4.2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Type (2017-2028)
  • 4.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type
    • 4.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Type (2017-2022)
    • 4.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Type (2023-2028)

5 Market Size by Application

  • 5.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application
    • 5.1.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Historical Sales by Application (2017-2022)
    • 5.1.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecasted Sales by Application (2023-2028)
    • 5.1.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Market Share by Application (2017-2028)
  • 5.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application
    • 5.2.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Historical Revenue by Application (2017-2022)
    • 5.2.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Forecasted Revenue by Application (2023-2028)
    • 5.2.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue Market Share by Application (2017-2028)
  • 5.3 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application
    • 5.3.1 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price by Application (2017-2022)
    • 5.3.2 Global Glucagon-like peptide 1 (GLP-1)-based Therapies Price Forecast by Application (2023-2028)

6 North America

  • 6.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type
    • 6.1.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2028)
    • 6.1.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2028)
  • 6.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
    • 6.2.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2028)
    • 6.2.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2028)
  • 6.3 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
    • 6.3.1 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2028)
    • 6.3.2 North America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2028)
    • 6.3.3 United States
    • 6.3.4 Canada

7 Europe

  • 7.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type
    • 7.1.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2028)
    • 7.1.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2028)
  • 7.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
    • 7.2.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2028)
    • 7.2.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2028)
  • 7.3 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
    • 7.3.1 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2028)
    • 7.3.2 Europe Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2028)
    • 7.3.3 Germany
    • 7.3.4 France
    • 7.3.5 U.K.
    • 7.3.6 Italy
    • 7.3.7 Russia

8 Asia Pacific

  • 8.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type
    • 8.1.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2028)
    • 8.1.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2028)
  • 8.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
    • 8.2.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2028)
    • 8.2.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2028)
  • 8.3 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Region
    • 8.3.1 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Region (2017-2028)
    • 8.3.2 Asia Pacific Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Region (2017-2028)
    • 8.3.3 China
    • 8.3.4 Japan
    • 8.3.5 South Korea
    • 8.3.6 India
    • 8.3.7 Australia
    • 8.3.8 China Taiwan
    • 8.3.9 Indonesia
    • 8.3.10 Thailand
    • 8.3.11 Malaysia

9 Latin America

  • 9.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type
    • 9.1.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2028)
    • 9.1.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2028)
  • 9.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
    • 9.2.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2028)
    • 9.2.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2028)
  • 9.3 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
    • 9.3.1 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2028)
    • 9.3.2 Latin America Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2028)
    • 9.3.3 Mexico
    • 9.3.4 Brazil
    • 9.3.5 Argentina

10 Middle East and Africa

  • 10.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Type
    • 10.1.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Type (2017-2028)
    • 10.1.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Type (2017-2028)
  • 10.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Application
    • 10.2.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Application (2017-2028)
    • 10.2.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Application (2017-2028)
  • 10.3 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Market Size by Country
    • 10.3.1 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Sales by Country (2017-2028)
    • 10.3.2 Middle East and Africa Glucagon-like peptide 1 (GLP-1)-based Therapies Revenue by Country (2017-2028)
    • 10.3.3 Turkey
    • 10.3.4 Saudi Arabia

11 Company Profiles

  • 11.1 Novo Nordisk
    • 11.1.1 Novo Nordisk Corporation Information
    • 11.1.2 Novo Nordisk Overview
    • 11.1.3 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.1.4 Novo Nordisk Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.1.5 Novo Nordisk Recent Developments
  • 11.2 AstraZeneca
    • 11.2.1 AstraZeneca Corporation Information
    • 11.2.2 AstraZeneca Overview
    • 11.2.3 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.2.4 AstraZeneca Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.2.5 AstraZeneca Recent Developments
  • 11.3 Eli Lily
    • 11.3.1 Eli Lily Corporation Information
    • 11.3.2 Eli Lily Overview
    • 11.3.3 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.3.4 Eli Lily Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.3.5 Eli Lily Recent Developments
  • 11.4 GSK
    • 11.4.1 GSK Corporation Information
    • 11.4.2 GSK Overview
    • 11.4.3 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.4.4 GSK Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.4.5 GSK Recent Developments
  • 11.5 Sanofi
    • 11.5.1 Sanofi Corporation Information
    • 11.5.2 Sanofi Overview
    • 11.5.3 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.5.4 Sanofi Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.5.5 Sanofi Recent Developments
  • 11.6 Bristol-Myers Squibb
    • 11.6.1 Bristol-Myers Squibb Corporation Information
    • 11.6.2 Bristol-Myers Squibb Overview
    • 11.6.3 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Sales, Price, Revenue and Gross Margin (2017-2022)
    • 11.6.4 Bristol-Myers Squibb Glucagon-like peptide 1 (GLP-1)-based Therapies Product Model Numbers, Pictures, Descriptions and Specifications
    • 11.6.5 Bristol-Myers Squibb Recent Developments

12 Industry Chain and Sales Channels Analysis

  • 12.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Chain Analysis
  • 12.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Key Raw Materials
    • 12.2.1 Key Raw Materials
    • 12.2.2 Raw Materials Key Suppliers
  • 12.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Production Mode & Process
  • 12.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales and Marketing
    • 12.4.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Sales Channels
    • 12.4.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Distributors
  • 12.5 Glucagon-like peptide 1 (GLP-1)-based Therapies Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

  • 13.1 Glucagon-like peptide 1 (GLP-1)-based Therapies Industry Trends
  • 13.2 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Drivers
  • 13.3 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Challenges
  • 13.4 Glucagon-like peptide 1 (GLP-1)-based Therapies Market Restraints

14 Key Findings in The Global Glucagon-like peptide 1 (GLP-1)-based Therapies Study

15 Appendix

  • 15.1 Research Methodology
    • 15.1.1 Methodology/Research Approach
    • 15.1.2 Data Source
  • 15.2 Author Details
  • 15.3 Disclaimer